All News

As part of its Speaking Out video series, CURE spoke Bruce L. Levine of the University of Pennsylvania Perelman School of Medicine about CAR-T cell therapy, what it means for young patients with cancer and what new horizons it has revealed for treatment.

As part of its Speaking Out video series, CURE spoke with Tom Whitehead, co-founder and president of the Emily Whitehead Foundation, about the process of seeking treatment and what resources are available for young patients with cancer and their families.

The FDA approved Ojjaara for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia.

Currently, the Food and Drug Administration lists 119 drugs as being in short supply, including 25 cancer drugs.

Although I know I am not a scientist, and understand my cancer may take a lifetime, I contemplate why I ended up with too many copies of the HER2 gene.

As The Los Angeles Rams celebrate a cancer survivor and a 9/11 survivor reveals his fourth cancer diagnosis, this is what’s happening in the oncology space this week.

Adding Imfinzi the pre- and post-surgical treatment for patients with non-small cell lung cancer led to improved results, research showed.

Blenrep improves durability and provides meaningful response rates to patients with relapsed/refractory multiple myeloma, researchers found.

CURE asked ChatGPT itself to write an article on the benefits of ChatGPT and artificial intelligence for patients with cancer and survivors.

So many aftereffects occurred with my two cancers.

Using a device such as a Fitbit or Apple Watch can make a big difference for patients and doctors.

The three-drug combination of Tagrisso plus platinum-based chemotherapy and pemetrexed boosted outcomes for patients with EGFR-mutant advanced non-small cell lung cancer.

Data revealed promising results for the combination of Trodelvy and Keytruda as a first-line treatment for patients with metastatic non-small cell lung cancer.

Patients "need to be proactive" as they coordinate care between two diseases.

I didn't have a choice but to get tattoos for my radiation.

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.

The TROPION-Lung04 trial reveals improvements from combining Dato-DXd with Imfinzi with or without carboplatin for patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed.

Researchers have found alternatives to opioid pills, which reduces the risk of misuse and addiction in patients undergoing pancreatic cancer surgery.

Recent developments in PARP inhibitor combinations and antibody-drug-conjugates are changing the landscape of ovarian cancer treatment.

“And… ok, that’s enough!” That was my brain’s reaction after the oncologist broke the news.

The recent FDA approval of Lonsurf plus Avastin for metastatic colorectal cancer improves survival and quality of life, an expert said.

The phase 2 ARROS-1 trial will investigate NVL-520 in patients with pretreated ROS1-positive non-small cell lung cancer or other solid tumors.

While PET scans have been used to predict Hodgkin lymphoma outcomes, adding Adcetris to frontline therapy improved outcomes for patients, regardless of their results.

Artificial intelligence platforms, including ChatGPT, offer many benefits, but some experts remain skeptical of the technology’s trustworthiness.

I don’t know about you, but music moves me. Literally. It makes me move.

The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma.

Patients with acute myeloid leukemia who took vitamin C and D supplements experienced fewer complications, but no overall survival benefits.

The phase 3 MARIPOSA- 2 study shows significant improvement within progression free survival after implementing Rybrevant into treatment for patients with non-small cell lung cancer.

Iclusig plust reduced-intensity bested Gleevec when it came to MRD-negative complete remission in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.